Giustina A et al (2020) Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord 21(4):667–678. https://doi.org/10.1007/s11154-020-09588-z

Article  PubMed  PubMed Central  Google Scholar 

Gadelha MR, Wildemberg LE, Kasuki L (2022) The future of somatostatin receptor ligands in acromegaly. J Clin Endocrinol Metab 107(2):297–308. https://doi.org/10.1210/clinem/dgab726

Article  PubMed  Google Scholar 

Bhat SZ, Salvatori R (2024) Current role of pasireotide in the treatment of acromegaly. Rec Adv Treat Acromegaly 38(4):101875. https://doi.org/10.1016/j.beem.2024.101875

Article  CAS  Google Scholar 

Gatto F et al (2019) Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells. Pituitary 22(1):89–99. https://doi.org/10.1007/s11102-018-0926-y

Article  CAS  PubMed  Google Scholar 

Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146(5):707–716. https://doi.org/10.1530/eje.0.1460707

Article  CAS  PubMed  Google Scholar 

Lesche S, Lehmann D, Nagel F, Schmid HA, Schulz S (2009) Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab 94(2):654–661. https://doi.org/10.1210/jc.2008-1919

Article  CAS  PubMed  Google Scholar 

Amarù J et al (2021) Octreotide and pasireotide combination treatment in somatotroph tumor cells: predominant role of SST2 in mediating ligand effects. Cancers. https://doi.org/10.3390/cancers13081816

Article  PubMed  PubMed Central  Google Scholar 

Gatto F et al (2017) In vitro head-to-head comparison between octreotide and pasireotide in gh-secreting pituitary adenomas. J Clin Endocrinol Metab 102(6):2009–2018. https://doi.org/10.1210/jc.2017-00135

Article  PubMed  Google Scholar 

Muhammad A et al (2018) Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression. J Clin Endocrinol Metab 104(3):915–924. https://doi.org/10.1210/jc.2018-01524

Article  Google Scholar 

Hofland LJ et al (2004) The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 89(4):1577–1585. https://doi.org/10.1210/jc.2003-031344

Article  CAS  PubMed  Google Scholar 

van der Hoek J et al (2005) The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. Clin Endocrinol (Oxf) 63(2):176–184. https://doi.org/10.1111/j.1365-2265.2005.02322.x

Article  CAS  PubMed  Google Scholar 

Petersenn S et al (2010) Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab 95(6):2781–2789. https://doi.org/10.1210/jc.2009-2272

Article  CAS  PubMed  Google Scholar 

Melmed S et al (2018) A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14(9):552–561. https://doi.org/10.1038/s41574-018-0058-5

Article  PubMed  PubMed Central  Google Scholar 

Fleseriu M et al (2021) A Pituitary Society update to acromegaly management guidelines. Pituitary 24(1):1–13. https://doi.org/10.1007/s11102-020-01091-7

Article  PubMed  Google Scholar 

Gadelha MR et al (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2(11):875–884. https://doi.org/10.1016/S2213-8587(14)70169-X

Article  CAS  PubMed  Google Scholar 

Fukunaga K et al (2021) Successful therapy using pasireotide long-acting release for Cushing’s disease merged with biochemical acromegaly. Intern Med Tokyo Jpn 60(7):1047–1053. https://doi.org/10.2169/internalmedicine.4663-20

Article  Google Scholar 

Fleseriu M, Rusch E, Geer EB, ACCESS Study Investigators (2017) Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study. Endocrine 55(1):247–255. https://doi.org/10.1007/s12020-016-1182-4

Article  CAS  PubMed  Google Scholar 

Silverstein J (2015) Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly. Neuro-Oncol. https://doi.org/10.1093/neuonc/nov206.30

Article  PubMed Central  Google Scholar 

Schmid HA et al (2016) Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine 53(1):210–219. https://doi.org/10.1007/s12020-016-0895-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S (2013) Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 98(8):3446–3453. https://doi.org/10.1210/jc.2013-1771

Article  CAS  PubMed  Google Scholar 

Chiloiro S et al (2022) Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly. Endocrine 78(2):343–353. https://doi.org/10.1007/s12020-022-03158-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

Corica G et al (2023) Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs. J Endocrinol Invest. https://doi.org/10.1007/s40618-023-02186-1

Article  PubMed  Google Scholar 

Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:71. https://doi.org/10.1136/bmj.n71

Article  Google Scholar 

Katznelson L et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951. https://doi.org/10.1210/jc.2014-2700

Article  CAS  PubMed  Google Scholar 

Sterne JAC et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https://doi.org/10.1136/bmj.l4898

Article  PubMed  Google Scholar 

Sterne JA et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https://doi.org/10.1136/bmj.i4919

Article  PubMed  PubMed Central  Google Scholar 

Egger M, DaveySmith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634. https://doi.org/10.1136/bmj.315.7109.629

Article  CAS  PubMed  PubMed Central  Google Scholar 

Colao A et al (2014) Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 99(3):791–799. https://doi.org/10.1210/jc.2013-2480

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tahara S et al (2017) Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study. Endocr J 64(7):735–747. https://doi.org/10.1507/endocrj.EJ16-0624

Article  CAS  PubMed  Google Scholar 

Shimon I et al (2018) Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study. Endocrine 62(2):448–455. https://doi.org/10.1007/s12020-018-1690-5